Cellectis stem cells today proudly announces the launch of the world’s very first human iPS cell-derived hepatocyte product
Published on
Gothenburg, Sweden, May 21st, 2012 – Cellectis stem cells, a Business Unit of Cellectis Group (Alternext: ALCLS), a premier provider of stem cell derived products and technologies, today announces the launch of a human iPS derived hepatocyte product, hiPS-HEP™.
Gothenburg, Sweden, May 21st, 2012 – Cellectis stem cells, a Business Unit of Cellectis Group (Alternext: ALCLS), a premier provider of stem cell derived products and technologies, today announces the launch of a human iPS derived hepatocyte product, hiPS-HEP™.
The hiPS-HEP™ demonstrate high reproducibility, homogeneity and a long life span of stable CYP activity, making them the ideal platform for various in vitro applications including drug discovery, toxicity testing and vaccine development. The hiPS-HEP™ are human hepatocyte-like cells derived from human induced Pluripotent Stem (iPS) cells under strict quality controlled and ethically approved procedures.
« Due to their high relevance in various industrial applications it makes the hiPS-HEP™ a really promising system for research and development », said Johan Hyllner, CSO of Cellectis stem cells. « The pharmaceutical industry has a great need for better and more clinically relevant models early in the drug development process to predict hepatotoxicity, find new drug targets and develop new vaccines. »
« This novel product is the fruition of Cellectis’ strategy to become the global market leader for stem cell-based in vitro models and related technologies. It illustrates our ambitions and the momentum of our future development in this field. » said André Choulika, Chairman and CEO of Cellectis.